Cargando…

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This d...

Descripción completa

Detalles Bibliográficos
Autores principales: Benko, Aleksandra, Medina-Cruz, David, Vernet-Crua, Ada, O’Connell, Catherine P., Świętek, Małgorzata, Barabadi, Hamed, Saravanan, Muthupandian, Webster, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019274/
https://www.ncbi.nlm.nih.gov/pubmed/35582024
http://dx.doi.org/10.20517/cdr.2020.81
_version_ 1784689224052637696
author Benko, Aleksandra
Medina-Cruz, David
Vernet-Crua, Ada
O’Connell, Catherine P.
Świętek, Małgorzata
Barabadi, Hamed
Saravanan, Muthupandian
Webster, Thomas J.
author_facet Benko, Aleksandra
Medina-Cruz, David
Vernet-Crua, Ada
O’Connell, Catherine P.
Świętek, Małgorzata
Barabadi, Hamed
Saravanan, Muthupandian
Webster, Thomas J.
author_sort Benko, Aleksandra
collection PubMed
description Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors.
format Online
Article
Text
id pubmed-9019274
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-90192742022-05-16 Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer Benko, Aleksandra Medina-Cruz, David Vernet-Crua, Ada O’Connell, Catherine P. Świętek, Małgorzata Barabadi, Hamed Saravanan, Muthupandian Webster, Thomas J. Cancer Drug Resist Review Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors. OAE Publishing Inc. 2021-06-19 /pmc/articles/PMC9019274/ /pubmed/35582024 http://dx.doi.org/10.20517/cdr.2020.81 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Benko, Aleksandra
Medina-Cruz, David
Vernet-Crua, Ada
O’Connell, Catherine P.
Świętek, Małgorzata
Barabadi, Hamed
Saravanan, Muthupandian
Webster, Thomas J.
Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title_full Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title_fullStr Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title_full_unstemmed Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title_short Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
title_sort nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019274/
https://www.ncbi.nlm.nih.gov/pubmed/35582024
http://dx.doi.org/10.20517/cdr.2020.81
work_keys_str_mv AT benkoaleksandra nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT medinacruzdavid nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT vernetcruaada nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT oconnellcatherinep nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT swietekmałgorzata nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT barabadihamed nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT saravananmuthupandian nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer
AT websterthomasj nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer